Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 8/20 | 0.64 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | CDK9 | P50750 | 2/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.45 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | CLK2 | P49760 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.45 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | PRKACA | P17612 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4362554 | 0.92 | AGPAT2 (0.64) | AGPAT2CDK9NOS1DYRK1AMAP4K4 | |
| SCHEMBL4359982 | 0.89 | KDR (0.51) | AGPAT2KDRNOS1ROCK2ROCK1 | |
| SCHEMBL4361700 | 0.83 | AGPAT2 (0.77) | AGPAT2CDK9JAK2ALDH1A1CDK5 | |
| SCHEMBL4361915 | 0.83 | AGPAT2 (0.85) | AGPAT2KDRCDK9ALDH1A1CDK5 | |
| SCHEMBL4370742 | 0.81 | AGPAT2 (0.56) | AGPAT2CDK9NOS1DYRK1AMAP4K4 | |
| SCHEMBL4363367 | 0.81 | AGPAT2 (0.53) | AGPAT2KDRNOS1DYRK1AMAP4K4 | |
| SCHEMBL4366686 | 0.81 | AGPAT2 (0.53) | AGPAT2KDRNOS1DYRK1AMAP4K4 | |
| SCHEMBL4362048 | 0.81 | AGPAT2 (0.81) | AGPAT2CDK9JAK2ALDH1A1CDK5 | |
| SCHEMBL29406206 | 0.78 | AGPAT2 (1.00) | AGPAT2CDK9ALDH1A1CDK5 | |
| SCHEMBL13622457 | 0.78 | AGPAT2 (1.00) | AGPAT2CDK9ALDH1A1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618968-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618968-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 35/4885KDR 2145/4885CDK9 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.